Xencor (XNCR) in Pivotal Point Check: 15% Price Explosion - Positive Phase-1 Data for Drug XmAb819 Leads to Reevaluation of the Biotech Platform!
Reading Time: 2 minutes
Convincing study data: Clinical results regarding the dose selection of the kidney cancer candidate XmAb819 impress the stock market. Clear development roadmap: The start of a potentially approval-relevant study is already planned for late 2027. Secured financing: The existing liquidity fully secures operational business until 2029. Xencor, a biotechnology company focused on developing modern antibody drugs for oncology and autoimmune diseases, made headlines on October 26, 2026, on the US technology exchange NASDAQ. The stock saw...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
